Clinical Trials
20 trialsNCT07217704 2026-06-02
FAPI-GO
SOFIE
Phase 3 Recruiting
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT05357846 2026-04-30
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT07177794 2026-04-21
EC-CRT-008
Sun Yat-sen University
Phase 3 Recruiting
NCT06964568 2026-04-17
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT04871412 2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT06676449 2026-01-07
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT04415853 2025-05-18
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT05865743 2025-03-05
PERSuaDER
Radboud University Medical Center
Phase 3 Recruiting
NCT05055648 2024-12-17
PROTECT
University of Aarhus
Phase 3 Recruiting
NCT04513808 2024-12-04
Total Intravenous Anesthesia and Recurrence Free Survival
The Cleveland Clinic
Phase 3 Recruiting
NCT06086457 2024-07-16
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT06339060 2024-07-03
PALACE3
Ruijin Hospital
Phase 3 Recruiting
NCT04280822 2022-10-04
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Henan Cancer Hospital
Phase 3 Recruiting
NCT05547529 2022-10-04
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
Blokhin's Russian Cancer Research Center
Phase 3 Recruiting
NCT05188313 2022-06-24
TRAP-2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Recruiting
NCT04135664 2019-10-22
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 3 Recruiting
NCT03731442 2018-12-12
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
ChineseAMS
Phase 3 Recruiting